The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs, e.g., imatinib, dasatinib and ponatinib) that bind to the ATP-binding site of Abl, has led to a remarkable clinical response to treat CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.